Study to Characterize the Distribution of Lipoprotein(a) Levels Among Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)

Brief description of study

Testing for elevated Lipoprotein(a) [Lp(a)] very rarely occurs in everyday clinical practice, despite its establishment as an important genetic cardiovascular (CV) risk factor. The 2018 American College of Cardiology/American Heart Association Cholesterol Guideline suggests individuals with Lp(a) levels =125 nmol/L (or =50 mg/dL) are at high risk.

Data relevant to the prevalence of patients with elevated Lp(a) in patients with established ASCVD, especially by country/region, is still sparse.

The purpose of this study is to characterize the distribution of Lp(a) levels among patients with a history of ASCVD as defined by their medical history and is 2-fold:

  • Evaluate the distribution of Lp(a) value in the overall patients with documented history of myocardial infarction (MI) and/or percutaneous coronary intervention (PCI).
  • Evaluate the distribution of Lp(a) value in patients with documented history of MI and/or PCI by demographics and regions.

  • Clinical Study Identifier: s22-00421

    If you are registered as a volunteer, please log in to contact the study team/express interest in this study.